{"id":403793,"date":"2020-12-21T09:56:06","date_gmt":"2020-12-21T14:56:06","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403793"},"modified":"2020-12-21T09:56:06","modified_gmt":"2020-12-21T14:56:06","slug":"medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/","title":{"rendered":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

By Global Stocks News<\/a><\/p>\n

\n VANCOUVER, BC<\/span>, Dec. 20, 2020<\/span> \/PRNewswire\/ – Medexus Pharmaceuticals (MDP.V)<\/a>\u00a0is a specialty\u00a0pharmaceuticals company that delivers innovative medicines to underserved segments of the market.<\/p>\n

With over 20,000 prescription drug products approved for marketing in North America<\/span><\/a>, the pharmacology space is fiercely competitive. Identifying “underserved markets” requires scientific, regulatory and business savvy.\u00a0 <\/p>\n

Medexus’ CEO Ken d’Entremont \u2013 a chemist by trade – is the former V.P of business development at Big Pharma company Sanofi, where he led the in-licensing initiatives for Sanofi Canada<\/a>.<\/p>\n

The current focus at MDP\u00a0includes rheumatology (arthritis\/joints\/muscles), auto-immune disease (diabetes\/MS\/lupus), specialty oncology (cancer) and pediatrics (child healthcare).<\/p>\n

On December 18, 2020<\/span> Medexus announced it has signed an exclusive license agreement with Ethypharm to register and commercialize Triamcinolone Hexacetonide Injectable Suspension<\/a> 20 mg\/mL (TH) in the U.S.<\/p>\n

TH is used to treat adults and teenagers suffering from arthritis. The effects last twice as long as competitive products.<\/p>\n

This exclusive agreement is expected to address existing supply chain issues, while reducing hospital visits and the need for general anesthetics.<\/p>\n

Physically active aging Baby Boomers are plagued by joint pain.\u00a0 Next year, the total number of people older than 65 years will jump to 656 million<\/a> (about 11% of the population).\u00a0 In California, the over-65 population is increasing at twice the speed of millennials.<\/p>\n

According to an Acumen Research Report<\/a>, t<\/b>he global Joint Pain Injections Market<\/b>\u00a0is estimated to grow at CAGR 8% in the next six years, to reach USD $5.7 billion<\/span> by 2026.<\/p>\n

Medexus expects to file for FDA approval of TH within 12-24 months.<\/p>\n

On November 16, 2020<\/span> Medexus published financial and operating results<\/a> for the three months ended September 30, 2020<\/span> (Q2, 2021).<\/p>\n

Medexus achieved revenue of $23.6 million<\/span> (CND) for the three-month period ended September 30, 2020<\/span>, a 40% increase over the same period, the previous year. <\/p>\n

The big revenue growth catalyst was the $3 million<\/span> quarterly revenue derived from IXINITY sales.<\/p>\n

IXINITY is used to treat Hemophilia B \u2013 a hereditary bleeding disorder.\u00a0 Hemophilia occurs in approximately 1 in 5,000 live births<\/a>.<\/p>\n

IXINITY was absorbed by MDP in February, 2020 in a “transformative acquisition<\/a>“.\u00a0 At that time, the product was booking 40% year-over-year growth. Since that event, the MDP stock price has risen 74%.<\/p>\n

MDP paid USD $30 million<\/span> for IXINITY.\u00a0 The purchase price was non-dilutive \u2013 coming from existing cash and a $20 million<\/span> credit facility with MidCap Financial.<\/p>\n

The U.S. hemophilia B market is approximately USD $734 million<\/span> and growing, with a highly concentrated prescriber base (limited number of physicians treating the disorder).<\/p>\n

“IXINITY is an FDA approved product with a track record of safety, efficacy and growing sales,” stated d’Entremont.<\/p>\n

The product is currently approved for patients 12 years and older. An MDP\u00a0Phase 4 clinical trial<\/a> is investigating the safety and efficacy of IXINITY for children. <\/p>\n

“The pediatric segment is estimated to represent one-third of the hemophilia B population,” stated d’Entremont, who is targeting “a label expansion” for IXINITY.<\/p>\n

“Medexus’ $95 million<\/span> 12-month trailing revenue is within 5% of its current market cap,” stated Global News CEO Guy Bennett<\/span><\/a> on December 20, 2020<\/span>, “By comparison, the $209 billion<\/span> Pfizer has 12-month trailing revenue of about $45 billion<\/span>, about 21% of its market cap”.<\/p>\n

Medexus has 43 dedicated North American sales reps.<\/p>\n

The November 16, 2020<\/span> financials reveal that Medexus’ selling and admin expenses decreased this quarter from 64.4% of revenue to 46.6% of revenue.<\/p>\n

\n Full Disclaimer<\/a>.<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/medexus-mdpv-expands-specialty-pharmaceuticals-portfolio-301196839.html<\/a><\/p>\n

SOURCE Global Stocks News<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire By Global Stocks News VANCOUVER, BC, Dec. 20, 2020 \/PRNewswire\/ – Medexus Pharmaceuticals (MDP.V)\u00a0is a specialty\u00a0pharmaceuticals company that delivers innovative medicines to underserved segments of the market. With over 20,000 prescription drug products approved for marketing in North America, the pharmacology space is fiercely competitive. Identifying “underserved markets” requires scientific, regulatory and business savvy.\u00a0 Medexus’ CEO Ken d’Entremont \u2013 a chemist by trade – is the former V.P of business development at Big Pharma company Sanofi, where he led the in-licensing initiatives for Sanofi Canada. The current focus at MDP\u00a0includes rheumatology (arthritis\/joints\/muscles), auto-immune disease (diabetes\/MS\/lupus), specialty oncology (cancer) and pediatrics (child healthcare). On December 18, 2020 Medexus announced it has signed an exclusive license agreement with Ethypharm to … <\/p>\n

Continue reading “Medexus (MDP.V) expands specialty pharmaceuticals portfolio”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403793","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire By Global Stocks News VANCOUVER, BC, Dec. 20, 2020 \/PRNewswire\/ – Medexus Pharmaceuticals (MDP.V)\u00a0is a specialty\u00a0pharmaceuticals company that delivers innovative medicines to underserved segments of the market. With over 20,000 prescription drug products approved for marketing in North America, the pharmacology space is fiercely competitive. Identifying “underserved markets” requires scientific, regulatory and business savvy.\u00a0 Medexus’ CEO Ken d’Entremont \u2013 a chemist by trade – is the former V.P of business development at Big Pharma company Sanofi, where he led the in-licensing initiatives for Sanofi Canada. The current focus at MDP\u00a0includes rheumatology (arthritis\/joints\/muscles), auto-immune disease (diabetes\/MS\/lupus), specialty oncology (cancer) and pediatrics (child healthcare). On December 18, 2020 Medexus announced it has signed an exclusive license agreement with Ethypharm to … Continue reading "Medexus (MDP.V) expands specialty pharmaceuticals portfolio"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T14:56:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medexus (MDP.V) expands specialty pharmaceuticals portfolio\",\"datePublished\":\"2020-12-21T14:56:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/\"},\"wordCount\":556,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=VA30090&sd=2020-12-21\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/\",\"name\":\"Medexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=VA30090&sd=2020-12-21\",\"datePublished\":\"2020-12-21T14:56:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=VA30090&sd=2020-12-21\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=VA30090&sd=2020-12-21\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medexus (MDP.V) expands specialty pharmaceuticals portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk","og_description":"PR Newswire By Global Stocks News VANCOUVER, BC, Dec. 20, 2020 \/PRNewswire\/ – Medexus Pharmaceuticals (MDP.V)\u00a0is a specialty\u00a0pharmaceuticals company that delivers innovative medicines to underserved segments of the market. With over 20,000 prescription drug products approved for marketing in North America, the pharmacology space is fiercely competitive. Identifying “underserved markets” requires scientific, regulatory and business savvy.\u00a0 Medexus’ CEO Ken d’Entremont \u2013 a chemist by trade – is the former V.P of business development at Big Pharma company Sanofi, where he led the in-licensing initiatives for Sanofi Canada. The current focus at MDP\u00a0includes rheumatology (arthritis\/joints\/muscles), auto-immune disease (diabetes\/MS\/lupus), specialty oncology (cancer) and pediatrics (child healthcare). On December 18, 2020 Medexus announced it has signed an exclusive license agreement with Ethypharm to … Continue reading \"Medexus (MDP.V) expands specialty pharmaceuticals portfolio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T14:56:06+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio","datePublished":"2020-12-21T14:56:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/"},"wordCount":556,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/","name":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21","datePublished":"2020-12-21T14:56:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=VA30090&sd=2020-12-21"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-mdp-v-expands-specialty-pharmaceuticals-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medexus (MDP.V) expands specialty pharmaceuticals portfolio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403793"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}